ADMA Biologics (ADMA) Stock Price, News & Analysis

Company Overview

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for patients with compromised or inadequate immune systems. The company’s activities include operating plasma collection centers, sourcing human plasma, and producing specialized immunoglobulin therapies.

ADMA’s marketed products include ASCENIV, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency disease; BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, a hepatitis B immune globulin used to provide protection against hepatitis B infection in certain clinical settings. The company also supports the manufacturing, distribution and commercialization of these therapies.

Founded in 2007 and headquartered in Boca Raton, Florida, ADMA Biologics serves the U.S. market through its plasma collection and manufacturing operations. The company’s leadership includes Adam S. Grossman, who serves as president and chief executive officer. ADMA’s products are developed for use in specialized immune-deficiency and infectious-disease applications.

Key Stats

• Today's Range: $9.20 to $9.50
• 50-Day Range: $8.27 to $10.06
• 52-Week Range: $7.21 to $20.46
• Volume: 2.27 million shs
• Average Volume: 1.75 million shs
• Market Capitalization: $2.07 billion
• P/E Ratio: 13.19
• Dividend Yield: N/A
• Price Target: $18.67
• Consensus Rating: Moderate Buy

ADMA Biologics Stock Analysis - MarketRank™

ADMA Biologics scored higher than 64% of companies evaluated by MarketBeat, and ranked 301st out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ADMA Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

ADMA Biologics has a consensus price target of $18.67, representing about 102.2% upside from its current price of $9.23.

Amount of Analyst Coverage

ADMA Biologics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.97%

Earnings Growth

Earnings for ADMA Biologics are expected to grow by 8.97% in the coming year, from $0.78 to $0.85 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ADMA Biologics is 13.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.90.

Price to Earnings Ratio vs. Sector

The P/E ratio of ADMA Biologics is 13.19, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.94.

Price to Book Value per Share Ratio

ADMA Biologics has a P/B Ratio of 4.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.09% of the float of ADMA Biologics has been sold short.

Short Interest Ratio / Days to Cover

ADMA Biologics has a short interest ratio ("days to cover") of 13.86, which indicates bearish sentiment.

Change versus previous month

Short interest in ADMA Biologics has recently increased by 5.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ADMA Biologics does not currently pay a dividend.

Dividend Growth

ADMA Biologics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.54

News Sentiment

ADMA Biologics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for ADMA Biologics this week, compared to 8 articles on an average week.

Search Interest

18 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

7 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ADMA Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.90% of the stock of ADMA Biologics is held by insiders.

Percentage Held by Institutions

75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/13/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ADMA
• CIK: 1368514
• Web: www.admabiologics.com
• Phone: (201) 478-5552
• Fax: 201-478-5553
• Employees: 647
• Year Founded: 2004

Price Target and Rating

• Average Price Target for ADMA Biologics: $18.67
• High Price Target: $21.00
• Low Price Target: $17.00
• Potential Upside/Downside: +102.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.70
• Trailing P/E Ratio: 13.19
• Forward P/E Ratio: 11.83
• P/E Growth: N/A
• Net Income: $146.93 million
• Net Margins: 32.98%
• Pretax Margin: 42.26%
• Return on Equity: 40.17%
• Return on Assets: 26.97%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 6.97
• Quick Ratio: 3.81

Sales & Book Value

• Annual Sales: $510.17 million
• Price / Sales: 4.05
• Cash Flow: $0.65 per share
• Price / Cash Flow: 14.11
• Book Value: $2.01 per share
• Price / Book: 4.59

Miscellaneous

• Outstanding Shares: 223,990,000
• Free Float: 215,250,000
• Market Cap: $2.07 billion
• Optionable: Optionable
• Beta: 0.78